Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Annals of Thoracic Medicine. 2010; 5 (2): 92-96
in English | IMEMR | ID: emr-129323

ABSTRACT

The principal aim of the present study was to determine whether Acinetobacter spp. Pneumonia differs from hospital-acquired pneumonias [HAPs] caused by other agents with respect to therapeutic success and survival rate. This study includes 140 adult patients diagnosed with HAPs caused by identified etiologic agents between March 2005 and February 2006. These patients were divided into two groups according to the agent responsible to their infection [Acinetobacter spp. [n=63] or non-Acinetobacter spp. [n= 77]]. The groups were compared in terms of risk factors, therapeutic success and six-week survival rates. Previous antibiotic use and the risk of aspiration were independent factors responsible for the development of Acinetobacter spp. pneumonia. Hypoalbuminemia, steroid use and the use of a mechanical ventilator were determined to be mortality-associated independent risk factors for Acinetobacter spp. pneumonia. The clinical success rate at the end of therapy was 41.6% and, at the sixth week, the survival rate was 35% among patients in whom Acinetobacter spp. was the causative agent. Conversely, in the control group, these values were 43 and 32%, respectively [P>0.05]. We found that the use of the appropriate antibiotics for the treatment of Acinetobacter spp. pneumonia was an important factor in survival [P <0.001]. The outcome of Acinetobacter spp. pneumonia do not differ from HAPs associated with non-Acinetobacter spp. in terms of therapeutic success and survival rates


Subject(s)
Humans , Male , Female , Actinobacteria , Treatment Outcome , Cross Infection , Risk Factors , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL